{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:08:47Z","timestamp":1795108127815,"version":"4.10.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Down syndrome regression disorder (DSRD) is a clinical symptom cluster consisting of neuropsychiatric regression without an identifiable cause. This study evaluated the clinical effectiveness of IVIg and evaluated clinical characteristics associated with relapse after therapy discontinuation. A prospective, multi-center, non-randomized, observational study was performed. Patients met criteria for DSRD and were treated with IVIg. All patients underwent a standardized wean-off therapy after 9\u201312 months of treatment. Baseline, on-therapy, and relapse scores of the Neuropsychiatric Inventory Total Score (NPITS), Clinical Global Impression-Severity (CGI-S), and the Bush\u2013Francis Catatonia Rating Scale (BFCRS) were used to track clinical symptoms. Eighty-two individuals were enrolled in this study. Patients had lower BFCRS (MD: \u22126.68; 95% CI: \u22128.23, \u22125.14), CGI-S (MD: \u22121.27; 95% CI: \u22121.73, \u22120.81), and NPITS scores (MD: \u22126.50; 95% CI: \u22127.53, \u22125.47) while they were on therapy compared to baseline. Approximately 46% of the patients (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200938) experienced neurologic relapse with wean of IVIg. Patients with neurologic relapse were more likely to have any abnormal neurodiagnostic study (\n                    <jats:italic>\u03c7<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200911.82,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.001), abnormal MRI (\n                    <jats:italic>\u03c7<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20097.78,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.005), and abnormal LP (\n                    <jats:italic>\u03c7<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u20095.45,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.02), and a personal history of autoimmunity (OR: 6.11,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) compared to patients without relapse. IVIg was highly effective in the treatment of DSRD. Individuals with a history of personal autoimmunity or neurodiagnostic abnormalities were more likely to relapse following weaning of immunotherapy, indicating the potential for, a chronic autoimmune etiology in some cases of DSRD.\n                  <\/jats:p>","DOI":"10.1038\/s41398-023-02579-z","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T12:01:56Z","timestamp":1691496116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-8234","authenticated-orcid":false,"given":"Jonathan D.","family":"Santoro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noemi A.","family":"Spinazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn A.","family":"Filipink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panteha","family":"Hayati-Rezvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Kammeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Sannar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhik K.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellad","family":"Khoshnood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Jafarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie K.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace Y.","family":"Gombolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison L.","family":"Christy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Real de Asua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3964-0123","authenticated-orcid":false,"given":"Maria","family":"del Carmen Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A.","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Van Mater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordan","family":"Worley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George T.","family":"Capone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen A.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2640-2094","authenticated-orcid":false,"given":"Michael S.","family":"Rafii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"2579_CR1","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/ajmg.a.37001","volume":"167a","author":"G de Graaf","year":"2015","unstructured":"de Graaf G, Buckley F, Skotko BG. Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am J Med Genet A. 2015;167a:756\u201367.","journal-title":"Am J Med Genet A"},{"key":"2579_CR2","doi-asserted-by":"crossref","unstructured":"Rosso M, Fremion E, Santoro SL, Oreskovic NM, Chitnis T, Skotko BG, et al. Down syndrome disintegrative disorder: a clinical regression syndrome of increasing importance. Pediatrics. 2020;145.","DOI":"10.1542\/peds.2019-2939"},{"key":"2579_CR3","doi-asserted-by":"publisher","first-page":"940175","DOI":"10.3389\/fneur.2022.940175","volume":"13","author":"JD Santoro","year":"2022","unstructured":"Santoro JD, Patel L, Kammeyer R, Filipink RA, Gombolay GY, Cardinale KM, et al. Assessment and diagnosis of Down syndrome regression disorder: international expert consensus. Front Neurol. 2022;13:940175.","journal-title":"Front Neurol"},{"key":"2579_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s11689-022-09446-w","volume":"14","author":"JD Santoro","year":"2022","unstructured":"Santoro JD, Partridge R, Tanna R, Pagarkar D, Khoshnood M, Rehmani M, et al. Evidence of neuroinflammation and immunotherapy responsiveness in individuals with Down syndrome regression disorder. J Neurodev Disord. 2022;14:35.","journal-title":"J Neurodev Disord"},{"key":"2579_CR5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41436-019-0706-8","volume":"22","author":"SL Santoro","year":"2020","unstructured":"Santoro SL, Cannon S, Capone G, Franklin C, Hart SJ, Hobensack V, et al. Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database. Genet Med. 2020;22:767\u201376.","journal-title":"Genet Med"},{"key":"2579_CR6","doi-asserted-by":"crossref","unstructured":"Walpert M, Zaman S, Holland A. A systematic review of unexplained early regression in adolescents and adults with Down syndrome. Brain Sci. 2021;11:1197.","DOI":"10.3390\/brainsci11091197"},{"key":"2579_CR7","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1177\/0883073814554654","volume":"30","author":"G Worley","year":"2015","unstructured":"Worley G, Crissman BG, Cadogan E, Milleson C, Adkins DW, Kishnani PS. Down syndrome disintegrative disorder: new-onset autistic regression, dementia, and insomnia in older children and adolescents with Down syndrome. J Child Neurol. 2015;30:1147\u201352.","journal-title":"J Child Neurol"},{"key":"2579_CR8","doi-asserted-by":"crossref","unstructured":"Mircher C, Cieuta-Walti C, Marey I, Marey I, Rebillat AS, Cretu L, et al. Acute regression in young people with Down syndrome. Brain Sci. 2017;7:57.","DOI":"10.3390\/brainsci7060057"},{"key":"2579_CR9","doi-asserted-by":"crossref","unstructured":"Santoro SL, Baumer NT, Cornacchia M, Franklin C, Hart SJ, Haugen K, et al. Unexplained regression in Down syndrome: Management of 51 patients in an international patient database. Am J Med Genet A. 2022;188:3049\u201362.","DOI":"10.1002\/ajmg.a.62922"},{"key":"2579_CR10","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/dmcn.14127","volume":"61","author":"KM Cardinale","year":"2019","unstructured":"Cardinale KM, Bocharnikov A, Hart SJ, Baker JA, Eckstein C, Jasien JM, et al. Immunotherapy in selected patients with Down syndrome disintegrative disorder. Dev Med Child Neurol. 2019;61:847\u201351.","journal-title":"Dev Med Child Neurol"},{"key":"2579_CR11","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41380-022-01845-8","volume":"28","author":"AJ Guastella","year":"2023","unstructured":"Guastella AJ, Boulton KA, Whitehouse AJO, Song YJ, Thapa R, Gregory SG, et al. The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial. Mol Psychiatry. 2023;28:834\u201342.","journal-title":"Mol Psychiatry"},{"key":"2579_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.3233\/JAD-201009","volume":"81","author":"LM Fonseca","year":"2021","unstructured":"Fonseca LM, Mattar GP, Haddad GG, Burduli E, McPherson SM, de Figueiredo Ferreira Guilhoto LM, et al. Neuropsychiatric symptoms of Alzheimer\u2019s disease in Down syndrome and its impact on caregiver distress. J Alzheimers Dis. 2021;81:137\u201354.","journal-title":"J Alzheimers Dis"},{"key":"2579_CR13","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/gps.587","volume":"17","author":"VP Prasher","year":"2002","unstructured":"Prasher VP, Huxley A, Haque MS. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer\u2019s disease-pilot study. Int J Geriatr Psychiatry. 2002;17:270\u20138.","journal-title":"Int J Geriatr Psychiatry"},{"key":"2579_CR14","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2147\/NDT.S210613","volume":"15","author":"JH Miles","year":"2019","unstructured":"Miles JH, Takahashi N, Muckerman J, Nowell KP, Ithman M. Catatonia in Down syndrome: systematic approach to diagnosis, treatment and outcome assessment based on a case series of seven patients. Neuropsychiatr Dis Treat. 2019;15:2723\u201341.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2579_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.2147\/NDT.S77307","volume":"11","author":"N Ghaziuddin","year":"2015","unstructured":"Ghaziuddin N, Nassiri A, Miles JH. Catatonia in Down syndrome; a treatable cause of regression. Neuropsychiatr Dis Treat. 2015;11:941\u20139.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2579_CR16","doi-asserted-by":"publisher","first-page":"e012356","DOI":"10.1136\/bmjopen-2016-012356","volume":"6","author":"MA Iro","year":"2016","unstructured":"Iro MA, Sadarangani M, Absoud M, Chong WK, Clark CA, Easton A, et al. ImmunoglobuliN in the treatment of encephalitis (IgNiTE): protocol for a multicentre randomised controlled trial. BMJ Open. 2016;6:e012356.","journal-title":"BMJ Open"},{"key":"2579_CR17","first-page":"Cd011367","volume":"10","author":"MA Iro","year":"2017","unstructured":"Iro MA, Martin NG, Absoud M, Pollard AJ. Intravenous immunoglobulin for the treatment of childhood encephalitis. Cochrane Database Syst Rev. 2017;10:Cd011367.","journal-title":"Cochrane Database Syst Rev"},{"key":"2579_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.neurol.2021.10.004","volume":"178","author":"E N\u2019Kaoua","year":"2022","unstructured":"N\u2019Kaoua E, Attarian S, Delmont E, Campana-Salort E, Verschueren A, Grapperon AM, et al. Immunoglobulin shortage: Practice modifications and clinical outcomes in a reference centre. Rev Neurol. 2022;178:616\u201323.","journal-title":"Rev Neurol"},{"key":"2579_CR19","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1093\/brain\/awac054","volume":"145","author":"ME Adrichem","year":"2022","unstructured":"Adrichem ME, Lucke IM, Vrancken A, Goedee HS, Wieske L, Dijkgraaf MGW, et al. Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Brain. 2022;145:1641\u201352.","journal-title":"Brain."},{"key":"2579_CR20","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.1093\/brain\/awaa326","volume":"143","author":"L Flores-Aguilar","year":"2020","unstructured":"Flores-Aguilar L, Iulita MF, Kovecses O, Torres MD, Levi SM, Zhang Y, et al. Evolution of neuroinflammation across the lifespan of individuals with Down syndrome. Brain 2020;143:3653\u201371.","journal-title":"Brain"},{"key":"2579_CR21","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10875-020-00805-7","volume":"40","author":"RHJ Verstegen","year":"2020","unstructured":"Verstegen RHJ, Kusters MAA. Inborn errors of adaptive immunity in Down syndrome. J Clin Immunol. 2020;40:791\u2013806.","journal-title":"J Clin Immunol"},{"key":"2579_CR22","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.celrep.2019.10.038","volume":"29","author":"KA Waugh","year":"2019","unstructured":"Waugh KA, Araya P, Pandey A, Jordan KR, Smith KP, Granrath RE, et al. Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in Down Syndrome. Cell Rep. 2019;29:1893\u20131908.e1894.","journal-title":"Cell Rep"},{"key":"2579_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13858-3","volume":"7","author":"KD Sullivan","year":"2017","unstructured":"Sullivan KD, Evans D, Pandey A, Hraha TH, Smith KP, Markham N, et al. Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation. Sci Rep. 2017;7:14818.","journal-title":"Sci Rep"},{"key":"2579_CR24","doi-asserted-by":"publisher","first-page":"724969","DOI":"10.3389\/fneur.2021.724969","volume":"12","author":"JD Santoro","year":"2021","unstructured":"Santoro JD, Lee S, Wang AC, Ho E, Nagesh D, Khoshnood M, et al. Increased autoimmunity in individuals with Down syndrome and Moyamoya disease. Front Neurol. 2021;12:724969.","journal-title":"Front Neurol"},{"key":"2579_CR25","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1515\/jpem-2016-0073","volume":"29","author":"T Aversa","year":"2016","unstructured":"Aversa T, Valenzise M, Corrias A, Salerno M, Lughetti L, Tessaris D, et al. In children with autoimmune thyroid diseases the association with Down syndrome can modify the clustering of extra-thyroidal autoimmune disorders. J Pediatr Endocrinol Metab. 2016;29:1041\u20136.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2579_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13052-015-0197-4","volume":"41","author":"T Aversa","year":"2015","unstructured":"Aversa T, Valenzise M, Salerno M, Corrias A, Lughetti L, Radetti G, et al. Metamorphic thyroid autoimmunity in Down Syndrome: from Hashimoto\u2019s thyroiditis to Graves\u2019 disease and beyond. Ital J Pediatr. 2015;41:87.","journal-title":"Ital J Pediatr"},{"key":"2579_CR27","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1177\/0009922820941247","volume":"59","author":"KK Ostermaier","year":"2020","unstructured":"Ostermaier KK, Weaver AL, Myers SM, Stoeckel RE, Katusic SK, Voigt RG. Incidence of celiac disease in Down syndrome: a longitudinal, population-based birth cohort study. Clin Pediatr. 2020;59:1086\u201391.","journal-title":"Clin Pediatr"},{"key":"2579_CR28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12887-017-0801-4","volume":"17","author":"JF Ludvigsson","year":"2017","unstructured":"Ludvigsson JF, Lebwohl B, Green PH, Chung WK, M\u00e5rild K. Celiac disease and Down syndrome mortality: a nationwide cohort study. BMC Pediatr. 2017;17:41.","journal-title":"BMC Pediatr"},{"key":"2579_CR29","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00125-010-1686-z","volume":"53","author":"TR Rohrer","year":"2010","unstructured":"Rohrer TR, Hennes P, Thon A, Dost A, Grabert M, Rami B, et al. Down\u2019s syndrome in diabetic patients aged <20 years: an analysis of metabolic status, glycaemic control and autoimmunity in comparison with type 1 diabetes. Diabetologia. 2010;53:1070\u20135.","journal-title":"Diabetologia."},{"key":"2579_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jpeds.2008.07.056","volume":"154","author":"H Juj","year":"2009","unstructured":"Juj H, Emery H. The arthropathy of Down syndrome: an underdiagnosed and under-recognized condition. J Pediatr. 2009;154:234\u20138.","journal-title":"J Pediatr"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02579-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02579-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02579-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T10:03:20Z","timestamp":1700388200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-023-02579-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,8]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2579"],"URL":"https:\/\/doi.org\/10.1038\/s41398-023-02579-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2521595\/v1","asserted-by":"object"}]},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,8]]},"assertion":[{"value":"27 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. JDS reports receiving federal funding from the NHLBI and NICHD for the study of autoimmune disease in persons with Down syndrome and the role of immunotherapy in persons with Down syndrome regression disorder. Drs. LP and RK also receive federal funding from the NICHD for the study of autoimmune disease in persons with Down syndrome and the role of immunotherapy in persons with Down syndrome regression disorder.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"276"}}